Results 21 to 30 of about 2,091 (88)

Melanoma Diagnosis in the Mihm Era—And Beyond

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 1, Page 16-22, January 2026.
ABSTRACT During the illustrious career of Martin C. Mihm Jr., MD, the diagnosis of melanoma underwent significant changes, to which he made many contributions. In early descriptions, melanomas were fungating tumor masses that were obviously malignant, and highly lethal. In seminal work by Dr. Mihm and his mentor, Wallace H.
David E. Elder
wiley   +1 more source

Ancient Schwannoma in the Nasal Cavity—A Rare Case Report With Brief Literature Review

open access: yes
Eye &ENT Research, Volume 3, Issue 3, Page 179-185, September 2026.
Shikhar Chohan   +2 more
wiley   +1 more source

Construction of a Competing‐Risk Nomogram for Predicting Cause‐Specific Mortality in Cutaneous Verrucous Carcinoma: A Retrospective SEER‐Based Study

open access: yesDermatologic Therapy, Volume 2026, Issue 1, 2026.
This retrospective observational cohort study aimed to develop and validate competing‐risk nomograms for predicting cancer‐specific survival (CSS) and noncancer‐specific death (OCD) in patients with cutaneous verrucous carcinoma (CVC). Data were extracted from the SEER database, including 649 eligible patients diagnosed between 2004 and 2015 across 18 ...
Siomui Chong   +14 more
wiley   +1 more source

A Diagnosis of Dysplastic Naevus has no Clinical Relevance and Unnecessarily Confounds Therapeutic Decision‐Making

open access: yesJEADV Clinical Practice, Volume 4, Issue 5, Page 969-981, December 2025.
ABSTRACT The term ‘dysplastic naevus’ first introduced in 1980, has since engendered considerable debate regarding its ontological legitimacy, the appropriateness of its nomenclature, and its potential prognostic significance. In this review, we undertake a critical examination of the extant literature, including a focus on the past decade.
Cliff Rosendahl   +5 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +206 more
wiley   +1 more source

Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment

open access: yesCancer, Volume 131, Issue 21, 1 November 2025.
Proteolysis‐targeting chimeras use the ubiquitin (Ub)–proteasome system to selectively break down oncogenic proteins, including previously undruggable targets. By providing long‐lasting suppression with lower toxicity, they are becoming a revolutionary approach for personalized cancer treatment.
Yamile Abuchard Anaya   +7 more
wiley   +1 more source

Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 21, Page 5340-5354, November 2025.
Background and Purpose Chemotherapeutic treatment for colorectal cancer (colorectal cancer) allows for increased patient overall survival. However, current therapeutic regimens are often associated with the development of adverse drug reactions, which represent a morbidity, mortality and economic issue.
Ana Rita Simoes   +20 more
wiley   +1 more source

Sudden cardiac arrest from commotio cordis in a competitive hurling athlete: case report. [PDF]

open access: yesEur Heart J Case Rep
Bruno G   +4 more
europepmc   +1 more source

Antepartum mental health disorders and hypertensive disorders of pregnancy: a retrospective cohort study using the premier healthcare administrative database (2016-2020). [PDF]

open access: yesInt J Obstet Anesth
Acuff HE   +9 more
europepmc   +1 more source

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. [PDF]

open access: yesNat Med
Porter ML   +22 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy